We investigated efficacy and toxicity of lenalidomide in 24 heavily pretreated myeloma patients with a median age of 59 years (range: 37-70) and relapse after allo-SCT. Lenalidomide was given at a dose of 15 mg (n ¼ 4), or 25 mg (n ¼ 20), orally once daily on day 1 to day 1 every 28 days, with (n ¼ 20) or without (n ¼ 4) DHAP. The median number of lenalidomide cycles was five (range: 2-17). Major side effects were leukopenia (grade 4: 4%, grade 3: 21% and grade 2: 17%) and thrombocytopenia (grade 3: 17% and grade 2: 29%); infectious complications were observed in 50%. Non-hematological toxicity consisted of muscle cramps (n ¼ 9), fatigue (n ¼ 5) and constipation (n ¼ 2). Mild grade I-II GVHD was seen in three patients. Response was achieved in 66%: CR in 8%, VGPR in 8%, PR in 50% and SD in 13%. The median time to progression was 9.7 months (95% confidence interval (CI): 7.5-11.9), and median OS was 19.9 months (95% CI: 17.3-22.5). Immunomonitoring after lenalidomide showed significant increase of activated NK (NKp44 þ ) and T (HLA-DR þ ) cells, as well as regulatory T cells (CD4 þ , CD25 þ , CD127 lo ), supporting an immunomodulating anti-myeloma effect of lenalidomide.
Introduction
Allo-SCT after reduced-intensity conditioning for patients with multiple myeloma has become an effective treatment option, especially in younger patients with multiple myeloma. [1] [2] [3] To upgrade remission or to prevent or to treat relapse, several therapies such as donor lymphocyte infusions, 4, 5 or novel agents such as bortezomib or thalidomide [6] [7] [8] [9] have been investigated after allo-SCT. As the so-called 'IMIDs' (immunomodulatory drugs), thalidomide and lenalidomide, induce enhanced T-cell activation and NK-cell activation, it could be a useful track to enhance graft-vs-myeloma effect after allo-SCT. Therefore, we investigated the efficacy of lenalidomide in 24 patients with multiple myeloma who had relapsed after allo-SCT. In eight patients, immunomonitoring of T-cell and NK-cell subpopulations before and after lenalidomide therapy was performed.
Patients
A total of 24 patients with a median age of 59 years (range: 37-70) were enrolled in this retrospective study. Revlimid was approved for salvage therapy and the study was performed according to institutional guidelines. For monitoring T and NK cells, patients gave written informed consent. A total of 12 patients had received stem cells from a related donor, and 12 patients from an unrelated donor. The median interval between allo-SCT and relapse was 18 months (range: 2-71). The median number of earlier chemotherapy cycles was six (range: 2-13). All patients had received at least one earlier allo-SCT; six patients had received two earlier autografts, and one patient had received three earlier autografts. Del 13q14 cytogenetic abnormalities as confirmed by interphase FISH was positive in 12 out of 18 patients.
The median interval between relapse after allo-transplantation and start of lenalidomide therapy was 11 months (range: 1-56). Other salvage therapies for relapse after allografting and before lenalidomide were donor lymphocyte infusion (n ¼ 18), thalidomide-containing regimens (n ¼ 11), bortezomib-containing regimens (n ¼ 13) or earlier radiotherapy (n ¼ 14). Only one patient received lenalidomide as first-line salvage therapy after failure to allograft. The median number of lenalidomide cycles was five (range: 2-7). Response was assessed according to the criteria of the European Group for Blood and Marrow Transplantation. 10 A total of 20 patients started with lenalidomide, 25 mg, and four patients with 15 mg, once daily on day 1 to day 21, every 28 days. DHAP was given in 20 patients in a dose of 40 mg weekly. In case of nontolerance or side effects, DHAP was reduced. Prophylactic anticoagulation was not used in any of the patients. The major characteristics of the patients are listed in Table 1 .
Immunomonitoring
In eight patients, serial measurement of peripheral T-cell and NK-cell subpopulations was performed before and after treatment with lenalidomide ( Table 2 ). The peripheral blood samples were collected before initiation of lenalidomide treatment and at two time points after treatment had been started (between day 30 and day 60, as well as between day 90 and day 120). Using cell counting and four color multiparameter flow cytometry, the following parameters were determined: the number of WBCs and lymphocytes per ml whole blood, the frequency of total T cells (CD3
In addition, we evaluated the expression of different surface receptors (CD94, CD158a/h, CD158b, CD158e, CD226, NKp30, NKp44, NKp46) on the surface of NK cells.
Results

Toxicity
The main toxicity was myelotoxicity: neutropenia grade 1 according to NCI criteria was seen in 29%, grade 2 in 17%, grade 3 in 21% and grade 4 in 4% of the patients. Thrombocytopenia grade 1 according to NCI criteria was seen in 25%, grade 2 in 29% and grade 3 in 17% of the patients. Myelotoxicity led to a dose reduction in 13 patients (54%), either to 15 mg or to 10 mg. Nonhematological toxicity was fever of unknown origin or infection in 12 patients, muscle cramps in nine patients, fatigue in five patients and constipation in two patients. No neurotoxicity was seen in this patient cohort. One patient developed a thrombo-embolic complication (cerebral infarction with neurological symptoms) that resolved completely. This patient was also treated with high-dose steroids for acute GVHD. GVHD while on treatment with lenalidomide occurred in three patients. All patients experienced GVHD of the skin, one grade II and two grade I.
Objective response was seen in 66% of the patients and occurred after a median of two cycles: CR was seen in 8%, very good PR in 8% and PR in 50%. A total of 13% of the patients achieved stable disease, and progressive disease was noted in 21% of the patients. Overall response rate was higher in patients with del(13) in comparison with those without del(13) (91 vs 50%; P ¼ 0.02). No influence of objective remission was seen with regard to earlier thalidomide treatment (55 vs 75%; P ¼ 0.3), earlier bortezomib treatment (56 vs 100%; P ¼ 0.07) and dose of lenalidomide (25 vs 15 mg) (59 vs 100%; P ¼ 0.011).
The median time to progression was 9.7 months (95% confidence interval (CI): 7.5-11.9). The time to progression was not influenced by the presence of del (13) , by earlier treatment of thalidomide or velcade, or by the achievement 
Results of immunophenotyping analyses
In the eight patients being investigated before and after the start of lenalidomide treatment, there were no significant changes (P 40.05, Student's t-test) in the WBC numbers, the frequency of total T cells, CD4 þ and CD8 þ T cells, NK cells and the expression of most NK-cell associated surface markers during therapy with lenalidomide. In contrast, the absolute number of lymphocytes ( Figure 1a Figure 1d ) (P ¼ 0.0008) showed a significant increase under lenalidomide. It is noted that the maximum number of activated NK and T cells was seen after about 3 months after initiation of lenalidomide therapy, whereas the maximum number of T-regulatory cells was seen 6 months after initiation of lenalidomide.
Discussion
This study with lenalidomide for relapsed patients after allo-SCT confirms the efficacy of this drug, which has been observed after failure to the standard therapy and auto-SCT. 11, 12 Neutropenia grades III and IV were seen in 25% of the patients, and were similar to 41.2 and 29.5% observed in both large lenalidomide/dexamethasone trials (MM009 and MM010). 11, 12 Myelotoxicity required dose reduction of lenalidomide in about 50% of the patients. Furthermore, the overall response rate of 66% (CR: 8%) was comparable to the MM009 (overall response rate: 61%; CR: 14.1%) and MM010 (overall response rate: 60.2%; CR: 15.9%) trials. 11, 12 The median time to progression of 9.7 months was slightly shorter than in the aforementioned lenalidomide/dexamethasone studies of 11.1 months and 11.3 months. This difference might be explained by the intensive pretreatment of this cohort, as all patients had received at least one autograft and one allograft. It is interesting to note that the presence of del(13q14) or earlier thalidomide or bortezomib treatment did not influence time to progression.
The second objective of this analysis was the investigation of the immune modulatory effects of post transplant lenalidomide treatment in multiple myeloma patients. Recently, the activity of lenalidomide after allografting has been studied in a small Dutch study. 13 This study showed high activity of lenalidomide ± dexamethasone in patients with multiple myeloma after failure to allo-SCT. In this study, an increase of regulatory T cells after lenalidomide treatment was observed. We observed a similar increase of T-regulatory cells after post transplant lenalidomide treatment, and in addition, a significant increase of activated T (HLA-DR þ ) cells and NK (NKp44 þ ) cells after post transplant lenalidomide therapy. This confirms previous observations of activation of NK and T cells after therapy with thalidomide or lenalidomide. 14, 15 This immunostimulating effect of lenalidomide might be an important mechanism of its anti-myeloma activity beside its anti-angiogenetic properties and its apoptotic effect. The increase of T-regulatory cells in myeloma patients remains unclear, 16 and after allo-SCT, Tregulatory cells seem to have a GVHD-protecting effect. 17 We recently observed that after allo-SCT in myeloma patients, T-regulatory cells expanded faster than conventional CD4 þ cells in BM, and that they expressed mainly CD45RA( À )/CCR7( À ) memory-T-cell phenotype. 18 The number of studied patients and samples are too small to draw definite conclusions, but the figures suggest a rapid increase of activated T and NK cells 1-2 months after treatment, and a decrease of the activated T and NK cells after 3-4 months, whereas the major increase of Tregulatory cells was seen mainly after 6 months. This might be interpreted as a counter-regulatory reaction to the increase of activated T and NK cells. In contrast to the Dutch study, we observed less GVHD, which might be due to the fact that in the Dutch trial the majority of the patients (especially those who developed severe GVHD) were not treated with lenalidomide in combination with dexamethasone, and seven patients had received donor lymphocyte infusion within 3 months before the start of Table 2 Results of lenalidomide salvage treatment after allo-SCT in multiple myeloma Lenalidomide after allo-SCT M Lioznov et al lenalidomide, which could at least have triggered GVHD lenalidomide might be useful for maintenance therapy or upgrading of remission after allo-SCT. On account of the observed myelotoxicity, a dose-finding study of lenalidomide as consolidation therapy after allo-SCT for multiple myeloma has been initiated. 
